The Biosecurity Modernization and Innovation Act of 2026 aims to strengthen the security and governance of biotechnology in the United States, particularly focusing on the synthesis of nucleic acids. This legislation seeks to prevent the misuse of synthetic nucleic acids, which could pose risks by enabling the creation of harmful pathogens. Key provisions include stringent requirements for biotechnology companies, known as "covered providers," that synthesize or sell synthetic nucleic acids.